hCAII-IN-8
|
H648109-25mg
|
≥99% |
952306-80-8 |
25mg
|
¥ 3600.9
|
期货,请咨询 |
阿拉丁 |
hCAII-IN-8
|
H648109-10mg
|
≥99% |
952306-80-8 |
10mg
|
¥ 1800.9
|
期货,请咨询 |
阿拉丁 |
HBT1
|
H648108-5mg
|
≥99% |
489408-02-8 |
5mg
|
¥ 500.9
|
期货,请咨询 |
阿拉丁 |
HBT1
|
H648108-50mg
|
≥99% |
489408-02-8 |
50mg
|
¥ 2500.9
|
期货,请咨询 |
阿拉丁 |
HBT1
|
H648108-25mg
|
≥99% |
489408-02-8 |
25mg
|
¥ 1600.9
|
期货,请咨询 |
阿拉丁 |
HBT1
|
H648108-10mg
|
≥99% |
489408-02-8 |
10mg
|
¥ 800.9
|
期货,请咨询 |
阿拉丁 |
HBT1
|
H648108-100mg
|
≥99% |
489408-02-8 |
100mg
|
¥ 4000.9
|
期货,请咨询 |
阿拉丁 |
Hex
|
H648086-5mg
|
≥99% |
2004714-32-1 |
5mg
|
¥ 6500.9
|
期货,请咨询 |
阿拉丁 |
Hex
|
H648086-10mg
|
≥99% |
2004714-32-1 |
10mg
|
¥ 10000.9
|
期货,请咨询 |
阿拉丁 |
β-Hydroxyisovalerylshikonin
|
H648056-5mg
|
≥99% |
7415-78-3 |
5mg
|
¥ 5140.9
|
期货,请咨询 |
阿拉丁 |
β-Hydroxyisovalerylshikonin
|
H648056-1mg
|
≥99% |
7415-78-3 |
1mg
|
¥ 1710.9
|
期货,请咨询 |
阿拉丁 |
Human PTHrP-(1-36)
|
H647873-5mg
|
|
172867-62-8 |
5mg
|
¥ 1800.9
|
期货,请咨询 |
阿拉丁 |
Human PTHrP-(1-36)
|
H647873-1mg
|
|
172867-62-8 |
1mg
|
¥ 600.9
|
期货,请咨询 |
阿拉丁 |
Human PTHrP-(1-36)
|
H647873-10mg
|
|
172867-62-8 |
10mg
|
¥ 2900.9
|
期货,请咨询 |
阿拉丁 |
Hardwickiic acid
|
H647856-1mg
|
≥98% |
1782-65-6 |
1mg
|
¥ 7000.9
|
期货,请咨询 |
阿拉丁 |
Harmalol hydrochloride
|
H647719-5mg
|
≥99% |
6028-07-5 |
5mg
|
¥ 1800.9
|
期货,请咨询 |
阿拉丁 |
Hck-IN-1
|
H647715-5mg
|
≥98% |
1473404-51-1 |
5mg
|
¥ 2800.9
|
期货,请咨询 |
阿拉丁 |
Hck-IN-1
|
H647715-50mg
|
≥98% |
1473404-51-1 |
50mg
|
¥ 11000.9
|
期货,请咨询 |
阿拉丁 |
Hck-IN-1
|
H647715-1mg
|
≥98% |
1473404-51-1 |
1mg
|
¥ 1333.9
|
期货,请咨询 |
阿拉丁 |
Hck-IN-1
|
H647715-10mg
|
≥98% |
1473404-51-1 |
10mg
|
¥ 4200.9
|
期货,请咨询 |
阿拉丁 |
HKB99
|
H647694-5mg
|
≥97% |
2414908-90-8 |
5mg
|
¥ 4760.9
|
期货,请咨询 |
阿拉丁 |
HKB99
|
H647694-10mg
|
≥97% |
2414908-90-8 |
10mg
|
¥ 7080.9
|
期货,请咨询 |
阿拉丁 |
Human PD-L1 inhibitor IV
|
H647662-5mg
|
≥99% |
2135542-83-3 |
5mg
|
¥ 2700.9
|
期货,请咨询 |
阿拉丁 |
Human PD-L1 inhibitor IV
|
H647662-1mg
|
≥99% |
2135542-83-3 |
1mg
|
¥ 950.9
|
期货,请咨询 |
阿拉丁 |